$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avidity Biosciences, Inc. (NASDAQ: RNA)

Core Insights - Class Action Attorney Juan Monteverde and his firm, Monteverde & Associates PC, are investigating Avidity Biosciences, Inc. regarding its proposed sale to Novartis AG, where Avidity shareholders would receive $72.00 per share in cash, raising questions about the fairness of the deal [1]. Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has a successful track record in recovering millions for shareholders [1][2]. - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2]. Legal Context - The investigation into Avidity Biosciences is part of a broader effort by the firm to ensure that shareholders' rights are protected in significant corporate transactions [1][3].